These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34033526)

  • 1. Gain-of-Function Polymorphisms in Human Inflammasomes: Implications for Cystic Fibrosis.
    Jeansonne D; Jeyaseelan S
    Am J Respir Cell Mol Biol; 2021 Aug; 65(2):126-127. PubMed ID: 34033526
    [No Abstract]   [Full Text] [Related]  

  • 2. Structure-function analysis of a double-mutant cystic fibrosis transmembrane conductance regulator protein occurring in disorders related to cystic fibrosis.
    Fanen P; Clain J; Labarthe R; Hulin P; Girodon E; Pagesy P; Goossens M; Edelman A
    FEBS Lett; 1999 Jun; 452(3):371-4. PubMed ID: 10386624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter characterization and validation of the intron-8 poly(T) tract (IVS8-T) status in 25 Coriell cell repository cystic fibrosis reference cell lines for cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation assays.
    Sebastian S; Spitzer SG; Grosso LE; Amos J; Schaefer FV; Lyon E; Wolff DJ; Hajianpour A; Taylor AK; Millson A; Stenzel TT
    Clin Chem; 2004 Jan; 50(1):251-4. PubMed ID: 14709668
    [No Abstract]   [Full Text] [Related]  

  • 4. The P2X7 Receptor in Cystic Fibrosis Monocytes: Linking CFTR Deficiency to Inflammation.
    Cantin AM
    Am J Respir Crit Care Med; 2022 Apr; 205(7):740-742. PubMed ID: 35139320
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations.
    Mickle JE; Cutting GR
    Clin Chest Med; 1998 Sep; 19(3):443-58, v. PubMed ID: 9759548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Modifier genes and cystic fibrosis].
    Corvol H; Flamant C; Vallet C; Clement A; Brouard J
    Arch Pediatr; 2006 Jan; 13(1):57-63. PubMed ID: 16274977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary genetic factors in cystic fibrosis lung disease.
    Mahadeva R; Lomas DA
    Thorax; 2000 Jun; 55(6):446. PubMed ID: 10817788
    [No Abstract]   [Full Text] [Related]  

  • 8. How do cystic fibrosis transmembrane conductance regulator mutations produce lung disease?
    Pilewski JM; Frizzell RA
    Curr Opin Pulm Med; 1995 Nov; 1(6):435-43. PubMed ID: 9363079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variation within the ovine cystic fibrosis transmembrane conductance regulator gene.
    Tebbutt SJ; Lakeman MB; Wilson-Wheeler JC; Hill DF
    Mutat Res; 1998 May; 382(3-4):93-8. PubMed ID: 9691989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystic fibrosis.
    Cuppens H; Dequeker E; Cassiman JJ
    Methods Mol Med; 2004; 92():221-44. PubMed ID: 14733315
    [No Abstract]   [Full Text] [Related]  

  • 11. Cystic fibrosis transmembrane regulator haplotypes in households of patients with cystic fibrosis.
    Furgeri DT; Marson FAL; Correia CAA; Ribeiro JD; Bertuzzo CS
    Gene; 2018 Jan; 641():137-143. PubMed ID: 29054758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of Cystic Fibrosis: Clinical Implications.
    Egan ME
    Clin Chest Med; 2016 Mar; 37(1):9-16. PubMed ID: 26857764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
    Perry LA; Penny-Dimri JC; Aslam AA; Lee TW; Southern KW
    Paediatr Respir Rev; 2017 Mar; 22():47-49. PubMed ID: 27964951
    [No Abstract]   [Full Text] [Related]  

  • 14. [Interference of P1290 P polymorphism (4002 A--> G) in molecular diagnosis of mucoviscidosis using the cystic fibrosis assay: an example of a diagnostic trap].
    Bienvenu T; Bousquet S; Souville I; Beldjord C
    Ann Biol Clin (Paris); 1999; 57(6):741-2. PubMed ID: 10572229
    [No Abstract]   [Full Text] [Related]  

  • 15. The genetics of cystic fibrosis.
    Pignatti PF
    Monaldi Arch Chest Dis; 1998 Dec; 53(6):603-5. PubMed ID: 10063328
    [No Abstract]   [Full Text] [Related]  

  • 16. Cystic fibrosis mutation frequencies in an Irish population.
    Devaney J; Glennon M; Farrell G; Ruttledge M; Smith T; Houghton JA; Maher M
    Clin Genet; 2003 Feb; 63(2):121-5. PubMed ID: 12630958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystic fibrosis: a further case of an asymptomatic compound heterozygote.
    White SM; Lucassen A; Norbury G
    Am J Med Genet; 2001 Nov; 103(4):342-3. PubMed ID: 11746017
    [No Abstract]   [Full Text] [Related]  

  • 18. Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein.
    Riordan JR
    Am J Hum Genet; 1999 Jun; 64(6):1499-504. PubMed ID: 10330337
    [No Abstract]   [Full Text] [Related]  

  • 19. French CF family genotype analysis shows that the R297Q mutation is a rare polymorphism.
    Dorval I; Jézéquel P; Chauvel B; Dubourg C; Fergelot P; Le Gall JY; Roussey M; Blayau M
    Hum Mutat; 1995; 6(4):334-5. PubMed ID: 8680407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic fibrosis and bone disease: defective osteoblast maturation with the F508del mutation in cystic fibrosis transmembrane conductance regulator.
    Velard F; Delion M; Le Henaff C; Guillaume C; Gangloff S; Jacquot J; Tabary O; Touqui L; Barthes F; Sermet-Gaudelus I
    Am J Respir Crit Care Med; 2014 Mar; 189(6):746-8. PubMed ID: 24628315
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.